Hyperlipen

Ciprofibrate, the active ingredient in Hyperlipen, is a fibrate presented as an oral formulation for oral use. It treats hypertriglyceridemia and mixed dyslipidemia in adult patients. GNH USA supplies Hyperlipen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Hyperlipen is a fibrate that acts on lipid metabolism to lower elevated triglyceride levels and improve overall lipid profiles. - Hypertriglyceridemia: reduces serum triglycerides and lowers risk of pancreatitis. - Mixed dyslipidemia: decreases triglycerides while modestly raising HDL‑cholesterol and lowering LDL‑cholesterol.

Common Side Effects: - Gastrointestinal discomfort: nausea, abdominal pain, or dyspepsia. - Headache: mild to moderate intensity. - Dizziness or light‑headedness. - Constipation or loose stools. - Elevated liver enzymes: mild, transient increases.

Serious or Rare Side Effects: - Myopathy or rhabdomyolysis, especially when combined with statins. - Severe hepatic dysfunction or hepatitis. - Gallstone formation. - Acute pancreatitis. - Anaphylactic or severe allergic reactions.

Before initiating therapy, clinicians should assess baseline liver and renal function and review concomitant medications. - Liver monitoring: check hepatic enzymes prior to treatment and periodically thereafter. - Renal monitoring: evaluate kidney function, especially in patients with pre‑existing impairment. - Gallbladder disease: avoid use in patients with active gallstones or biliary disease. - Statin co‑therapy: assess risk of myopathy and adjust doses if necessary. - Pregnancy and lactation: use only if potential benefits justify potential risks. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Ciprofibrate may interact with several drug classes, requiring careful management. Major Interactions (Avoid): - Statins (especially high‑dose): increased risk of myopathy and rhabdomyolysis. - Gemfibrozil: additive effect on muscle toxicity. - Warfarin: potentiation of anticoagulant effect, requiring INR monitoring. Moderate Interactions (Monitor Closely): - Niacin: heightened flushing and potential liver stress. - Digoxin: possible increase in serum digoxin concentrations.